@Article{Rehman2021,
journal="Clinical and Experimental Hepatology",
issn="2392-1099",
volume="7",
number="3",
year="2021",
title="Overview of lenvatinib as a targeted therapy 
for advanced hepatocellular carcinoma",
abstract="Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Patients commonly present with advanced/unresectable HCC where several treatment options are not effective. In this review, the authors discuss the indications and usage of lenvatinib, a multikinase inhibitor, as first-line therapy for advanced/unresectable HCC, its mode of action, efficacy, drug reactions, response to treatment and adverse effects. Since its approval in 2007, sorafenib has been used as first-line therapy for unresectable HCC. In 2018, a phase III multinational REFLECT trial on subjects with unresectable HCC (Child-Pugh class A) demonstrated that lenvatinib was non-inferior compared to sorafenib for overall survival, with a controllable toxicity profile, leading to its approval. In addition, our review discusses studies that compare the safety and efficacy profile of lenvatinib especially in patients who have a decline in their liver function to Child-Pugh class B. A current real world analysis of lenvatinib approval for unresectable HCC worldwide is reported.",
author="Rehman, Obaid
and Jaferi, Urooj
and Padda, Inderbir
and Khehra, Nimrat
and Atwal, Harshan
and Mossabeh, Dina
and Bhangu, Ranvir",
pages="249--257",
doi="10.5114/ceh.2021.109312",
url="http://dx.doi.org/10.5114/ceh.2021.109312"
}